Genetic deletion or pharmacological inhibition of NLRP3 in mice significantly suppresses tissue inflammation and improves pathological features of NASH such as fibrosis and insulin resistance [129]. Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.